All In Biotech

Drug Trial Radar · NCT03975374

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jun 15, 2019

Primary completion

Jul 1, 2019

Study completion Jun 30, 2020

Sponsor

Lead sponsor
Sutphin DrugsIndustry
Sponsor type
Industry
First posted
Jun 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters

Conditions

  • Blepharo Conjunctivitis

Interventions

  • Tobramycin/dexamethasone opthalmic solutionDrug

    To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution

  • Tobradex Opthalmic SolutionDrug

    Tobradex Opthalmic Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sign and symptoms composite scoreTime frame: 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sutphin Drugs

    Jamaica, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.